Comment: Assessing humoral immunocompetence after alemtuzumab treatment in MS

Neurology

Volumn 81, Issue 10, 2013, Pages 875-

  Cross, Anne H ^a   Klein, Robyn S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; CD4 ANTIGEN; CD52 ANTIGEN; CD8 ANTIGEN;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; B LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG HALF LIFE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPETENCE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENCE RISK; T LYMPHOCYTE; VACCINATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMMUNOCOMPETENCE; MALE; MULTIPLE SCLEROSIS;

EID: 84884631260     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182a352c6     Document Type: Note

References (3)

1. Coles AJ. Alemtuzumab therapy for multiple sclerosis. Neurotherapeutics 2013;10: 29-33.
2. Hill-Cawthorne GA, Button T, Tuohy O, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83:298-304.
3. McCarthy CL, Tuohy O, Compston DAS, Kumararatne DS, Coles AJ, Jones JL. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology 2013;81:872-876.